Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Front-line rotating imatinib and nilotinib for Philadelphia chromosome-positive acute lymphoblastic leukemia in elderly or unfit adults
2009-013271-22Phase 2Completed
- Sponsor
- GIMEMA
- Start
- Nov 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nilotinib and imatinib in acute lymphoblastic leukemia (ALL), sponsored by GIMEMA. Primary endpoint: Disease-free survival at 24 weeks. Started Nov 2009; status: completed.
02
Drugs
nilotinibimatinib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2009-013271-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013271-22.